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 Introduction 
 Manufacturing of medicines in Ethiopia started in 1964 with the estab-
lishment of one joint venture manufacturing company. This company 
remained the sole producer of medicines throughout the military regime 
(1974–91). Following the regime change in 1991, several manufacturing 
plants were established during the period referred to as the ‘boom 
and crash’ period, since, for reasons described below, some of the new 
companies were not successful. To respond to the crisis, the government 
took a mix of initiatives, simultaneously fulfilling its responsibility for 
health care improvement and industrial promotion. As a result of policy 
adjustments and attractive incentives, the environment for investment 
in pharmaceuticals became conducive, prompting private initiative to 
engage in industrial investment. Joint ventures that were realized have 
not only contributed to the pharmaceutical industry; they also effec-
tively transferred skill and technology. 
 This chapter argues for the importance of integrating the health and 
industrial policies to foster local pharmaceutical production. We argue 
that local production of pharmaceuticals is justified from both industrial 
and health polices standpoints. From an industrial policy standpoint, 
local pharmaceutical manufacture is usually justified by its benefits 
for the local economy, such as savings on foreign exchange through 
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import substitution, employment creation and the development of 
exports. From a health policy perspective, the rationale for local phar-
maceutical manufacture is largely founded on increasing the access to 
essential medicines. Ethiopia is a country with high disease burden; it 
therefore considers development of the pharmaceutical industry a stra-
tegic endeavour. 
 The chapter is organized to demonstrate the close interconnections 
between industrial and health improvement in recent Ethiopian expe-
rience. After an overview of the stages of pharmaceutical industrial 
development in Ethiopia over the last 50 years, the chapter turns to an 
examination of the context and framework of Ethiopian health policies 
and the supply of medicines, describing the importance of medicines 
demand for the industry and industrial supply for health sector devel-
opment. We describe how the health sector development programme is 
linked to the provision of essential medicines in the primary health care 
(PHC) system of the country, and the government’s social responsibility 
in providing medicines to the population. 
 A key objective of the chapter is to argue, on Ethiopian evidence, 
that joint ventures in the pharmaceutical industry can be designed as 
strategic partnerships. It narrates some success stories in terms of tech-
nology transfer and upgrading manufacturing plants, and localization 
of knowledge within Ethiopia, and their roots in a conducive policy 
environment for private sector investment. A final section examines 
these developmental aspects of Ethiopian industrial policies. In conclu-
sion we acknowledge the headway Ethiopia has made in manufacturing 
medicines and identify some issues to be addressed. 
 In the preparation of this chapter, policy documents, proclamations, 
regulations, guidelines and literature were reviewed. Key informant 
interviews were conducted and plant visits undertaken by the authors. 
 Pharmaceutical industrial development in Ethiopia 
 Phases of industrial development 
 The history of pharmaceutical manufacturing in Ethiopia is only half 
a century old and it may be classified into three periods: the estab-
lishment of the Ethiopian Pharmaceutical Manufacturing company 
(EPHARM), the subsequent boom and crash and the later ‘reform and 
revival’ period. 
 The first pharmaceutical manufacturing plant in Ethiopia, EPHARM 
was founded in 1964 as a joint venture by the Ethiopian government 
and the British company, Smith & Nephew. In 1971, Smith & Nephew 
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was superseded by Teva Jerusalem of Israel. Following the overthrow 
of the monarchial government by the military in December 1975, the 
company was nationalized. Due to the socialistic policy of the military 
regime, private industrial investment generally stagnated and EPHARM 
remained the sole producer of medicines in the country until 1993. In 
February 1994, EPHARM was re-established as a public share holding 
company and recently it was sold to a local investor. 
 The period 1995 to 2004 experienced the boom and crash. Ten new 
pharmaceutical plants were established: Asmi Industry PLC, East African 
Pharmaceuticals (EAP), Addis Pharmaceuticals Factory (APF), ETAB PLC, 
Pharmacure PLC, BioSol PLC, Life-Line PLC, Fews PLC, Sino-Ethiop 
Associate (Africa) PLC (SEAA) and Bethelehem PLC. However, the new 
factories faced daunting challenges, as there were neither policies nor 
regulatory mechanisms to control dumping of cheaper and substandard 
products. The prices of local products were not competitive. In addi-
tion, most of the new factories were poorly organized and managed. 
Consequently, four companies were foreclosed for failure to service their 
loan obligations. 
 According to the secretary of the Ethiopian Pharmaceuticals and 
Medical Supplies Manufacturing Association (PMSMA), the produc-
tion capacities of the majority of the industries at the time was below 
50% of their installed capacity. There was a high tariff on raw mate-
rials and a chronic shortage of experienced human resources, associated 
with high turnover of technical staff, shortage of technical manpower, 
and an absence of any training centre on good manufacturing practices 
(GMP) and pharmaceutical management. In addition there were no 
GMP-certified inspectors at the regulatory authority. It was hard to get 
working capital from banks, there were management problems in the 
industries, an absence of qualified equipment calibration and mainte-
nance centres, and university-industry linkages were weak. 
 Established in 1996, East African Pharmaceuticals (EAP) was one of 
the companies that survived the ‘crash’ period. EAP was an initiative 
of British and Sudanese nationals. It had difficulties at the outset when 
the cost of the investment was driven up due to the decision of Drug 
Administration and Control Authority (DACA) that EAP should recon-
struct its plant to comply with GMP, shortly after it started operation. 
In 2009, the factory was operating at 30% of its capacity. EAP produces 
human and veterinary medicines mainly for the local market, although 
a small portion is exported to Sudan and Somali. Being the only local 
manufacturing company producing veterinary medicines, EAP enjoys 
market monopoly. Hence, it is currently considering increasing its 
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production to meet the market demand. At the time of writing EAP has 
just achieved a GMP Certificate from the Pharmaceutical Inspection 
Convention and Pharmaceutical Inspection Co-operation Scheme 
(PIC/S). 
 Established in 1997, Addis Pharmaceuticals Factory (APF) Sh. Co. is 
the largest pharmaceutical manufacturing plant in Ethiopia. It is located 
in Adigrat, Tigray Regional State, northern Ethiopia. Though the plant 
was constructed and equipped with high-tech production facilities, at 
the start it faced financial and management crisis. In 2009, it acquired a 
second factory located at Akaki at the outskirts of Addis Ababa, which is 
dedicated to the manufacturing of large-volume parenterals. APF manu-
factures about 90 products. It has nine production lines with a capacity 
to produce 1.2 billion tablets, 19 billion ampoules, 10 million vials, 
500,000 capsules, 4 million ointment tubes and 9.6 million bottles of 
syrup. It has fully equipped laboratories. APF is owned and managed by 
the Endowment Fund for the Rehabilitation of Tigray (EFFORT). 1 
 Sino-Ethiop Associate (Africa) PLC (SEAA) was established in 
March 2001 as a joint venture between an Ethiopian company, Zaf 
Pharmaceuticals PLC, and two Chinese companies (China Associate 
Group and Dandong JINWAN Group). SEAA produces empty hard 
gelatin capsules and sells them to pharmaceutical factories in Africa and 
the Middle East. Recently, SEAA completed its expansion project and 
doubled its production capacity, to 2.4 billion capsules annually. SEAA 
has recently acquired Certificate of PIC/S conformity. It will be shown 
later that companies established through joint venture have been gener-
ally successful. 
 The ‘reform and revival’ period began in 2005. The Ethiopian 
Pharmaceutical and Medical Supplies Manufacturers Association 
(EPMSMA) and other key stakeholders appealed to the government for 
appropriate measures to be taken in support of local manufacturing. To 
address the crisis the local manufacturers were facing, the government 
created benefit packages and undertook policy reforms. This improved 
the business environment, resulting in some new joint ventures. 
 In 2007, Cadila Pharmaceuticals Ethiopia PLC (CPEL) was established 
by Cadila Pharmaceuticals Ltd (India) and Almeta Impex PLC (Ethiopia), 
owning 57% and 43% of the company, respectively. The market size, 
including easy access from Ethiopia to other East African countries, moti-
vated the investment. All machines and raw materials were imported 
from India. CEPL has the capacity to manufacture 390 million tablets, 
165 million capsules and 1.44 million litres of liquid per annum. In 
2011, CEPL acquired a GMP certificate. 2 
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 Established in 1998, Pharmacure PLC, a Swedish turnkey plant, is an 
Ethiopian-Saudi investment. It produces large-volume parenterals. Rx 
Africa (Ethiopia) PLC, an Ethiopian-US joint venture was commissioned 
in 2007 through the acquisition of a local company called Sunshine 
Pharmaceuticals. Rx Africa launched 36 products in 2009. Another local 
manufacturer, Fews PLC, produces syrups. 
 In 2013, Julphar (Gulf Pharmaceutical Industries) commissioned its 
pharmaceutical manufacturing facility 3 in Addis Ababa. The facility has 
the capacity to produce 150 million bottles of suspension and syrup, 
500 million tablets and 170 million capsules annually. 
 One unique local manufacturer is the National Veterinary Institute 
located in Bishoftu, 40 km south of Addis Ababa. With its well-equipped 
diagnostic and research laboratories and production plants, the NVI is 
currently producing 19 R&D-based veterinary bacterial and viral vaccines 
for both domestic and international markets to more than 25 countries 
in Africa and the Middle East. 
 The Ethiopian industry today 
 Today, the Ethiopian pharmaceutical industry consists of 15 pharma-
ceutical manufacturers, of which nine produce medicines, one manu-
factures empty gelatin capsules, and the rest are engaged in producing 
medical supplies such as syringes, absorbent cottons, gauzes, bandages 
and sanitary products. Though significant expansion of the industry is 
taking place, as such the base is not yet well developed, and the compa-
nies have relatively low production capacities. 
 The therapeutic categories of local production include antibiotics, 
gastrointestinal drugs, central nervous system drugs, cardiovascular 
drugs, anti-diabetic agents, antihistamines, anthelmintics, analge-
sics and antipyretics, antiprotozoals, respiratory drugs, dermatological 
preparations, minerals and vitamins, large-volume parenterals as well 
as veterinary vaccines. None of the manufacturers produces medicines 
against tuberculosis, HIV/AIDS and malaria. Since the local manufac-
turers were not GMP-compliant, they could not make use of the donor 
funding made available for the procurement of medicines for these 
diseases. Hence these medicines are being imported from abroad, mainly 
from Indian manufacturers. 
 The Ethiopian pharmaceutical industries are small- to medium sized 
industries. Most use labour-intensive, step-by-step manual manufac-
turing, with semi-automated production lines. Manufacturers mainly 
focus on tablets, capsules, powder and liquid preparations. A few produce 
parenteral preparations, creams and ointments. Production is limited 
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to secondary manufacturing that involves combining and processing 
pharmaceutical active ingredients (APIs) and excipients into dosage 
forms. There is no active pharmaceutical ingredient (API) plant in the 
country. Almost all input materials (APIs and excipients), including 
primary packaging materials, are imported, mainly from India and 
China. According to an interview with the procurement department 
manager of EPHARM, input materials are purchased in small quantities, 
at times too small to attract suppliers, and as a result manufactures have 
no power to negotiate better prices. This situation tends to increase the 
cost of input materials. Hence, most of the finished products are not 
competitive as compared to products imported from China and India. 
Just a few inputs such as sugar (for syrup production), empty hard 
gelatin capsules and secondary packing materials are locally produced. 
There are new packaging manufacturers who have begun producing 
PVC and empty bottles for pharmaceutical use replacing some of the 
imports (Sutton and Kellow, 2010). Cardboard boxes for bulk packaging 
are manufactured locally. 
 Although most of the manufacturers operate below their respective 
capacities, the capacity utilization of the manufacturers has shown 
improvement during the 2005–14 period, increasing from a mere 29.3% 
in 2008 to 79.0% in 2013. This is indicative of the growing market for 
locally produced pharmaceuticals – an opportunity lying ahead for the 
sector (CSA, 2014). 
 As regards quality issues, there are three manufacturers that comply 
with basic GMP standards, one of whom is to acquire PIC/S Certification 
soon, while two others are expected to acquire the same in the near 
future. One of the main issues that must be addressed by local manufac-
turers is the need to access updated technology. In terms of personnel, 
however, Ethiopia seems to have sufficient trained pharmacists, though 
there is a dire need for those with industrial and managerial skills. 
 Developing and supplying the health sector 
 This section analyses the interaction of health care development and 
industrial market development, aiming to show how health and medi-
cines policies influenced the development of the local pharmaceutical 
industry. 
 The National Health Policy (NHP) launched in 1993 includes as core 
elements the development of preventive, promotive and curative health 
care; assurance of health care accessibility for all segments of the popu-
lation; and the promotion of private sector and NGO participation 
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in the health sector (TGE, 1993a). In order to achieve these goals, a 
20-year Health Sector Development Programme (HSDP) consisting of 
a series of five-year rolling programmes was established in 1997/98. 
The HSDP has been aligned with the wider frameworks of the Plan for 
Accelerated Development to End Poverty (PASDEP), and a Growth and 
Transformation Plan (GTP) has been formulated and implemented. 
 HSDP implementation takes a sector-wide approach encompassing 
the following components: service delivery and quality of care; health 
facility rehabilitation and expansion; human resource development; 
pharmaceutical services; information, education and communication; 
health sector management and management of information systems; 
monitoring and evaluation and health care financing. 
 Over the last two decades the government has been engaged in health 
facility construction, expansion, rehabilitation, furnishing and equip-
ping. From 2003/04 to 2011, the number of health posts increased from 
4,696 to 17,972 and the number of public health centres from 519 to 
3,871, while the number of hospitals (public and private) rose from 
126 to 194 (FMOH, 2011). Health service coverage increased from 45% 
in 2001 to 95% by 2011. The rise in health service coverage necessi-
tated an increased demand for pharmaceuticals. Hence, the number of 
pharmaceutical manufacturers, importer/distributors and retail outlets 
increased significantly during the same period to serve an expanding 
market. 
 Targets set by HSDP IV with respect to pharmaceutical supply and 
services include increasing the availability of quality pharmaceuti-
cals at an affordable price and in a sustainable manner, and achieving 
improved rational drug use. In the design of HSDP III and IV, the SWOT 
analysis made indicated increasing domestic manufacturing capacity of 
drugs as an opportunity to be explored (FMOH, 2011/12). Recognizing 
the importance of the supply of pharmaceuticals in the overall health 
policy, the government decided to increase the availability of essential 
pharmaceuticals from 75% to 100% and improve the efficiency of regula-
tory activity (MOFED, 2006). Moreover, the Growth and Transformation 
Plan (GTP) anticipated increasing the domestic market share of the local 
pharmaceutical industry from the baseline year 2009/10 share of 15% to 
the target 50% (MOFED, 2012). 
 The market for pharmaceuticals in Ethiopia is met through import 
(purchase and donation) and local production. Local manufacturing still 
represents less than 15% of the total market for pharmaceutical prod-
ucts. Governmental organizations, private importers, non-government 
organizations (NGOs) and international agencies such as the UNICEF 
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and WHO used to participate in the import and distribution of pharma-
ceuticals. In order to streamline the supply and distribution of essential 
medicines to the public health care facilities, the former PHARMID was 
transformed into the Pharmaceutical Fund and Supply Agency (PFSA), as 
established by Proclamation in 2007 (FDRE, 2007). 
 Today, local and international procurement for the public health facil-
ities is mainly provided by the PFSA which operates with a revolving 
fund. PFSA procurement is done through international and local tenders 
as well as through direct purchasing. The PFSA also receives some phar-
maceuticals through donation from sponsors of vertical programmes 
such as those for ARVs, TB and malaria medication and reproductive 
health commodities. From its central hub in Addis Ababa and the 
regional hubs, PFSA distributes medicines and medical supplies directly 
to health care facilities. Private companies import directly from their 
respective suppliers and distribute to wholesalers, and these in turn sell 
to retailers. 
 The PFSA has designed and implemented different strategies to 
support local manufacturers of pharmaceuticals and medical supplies. 
These include the provision of 30% advance payment for the purchase 
of products won through national bidding and 25% price preference 
when local manufacturers participate in international bids. Although 
not yet implemented, a tripartite agreement (PFSA as a collateral, phar-
maceutical companies and the Development Bank) has been signed, 
providing local manufacturers with a loan for 70% of a bid that has 
been won. Furthermore, to increase local production of pharmaceuticals 
and medical supplies and create market linkages with consumers, the 
type and amount of products given priority by the health services have 
been identified. Based on this, a list of 124 pharmaceuticals and medical 
supplies produced in the country has been prepared to serve as a guide 
for the procurement process. 
 With an estimated population of 95 million in 2014, Ethiopia has 
the potential to become a significant market for pharmaceutical 
products in Sub-Saharan Africa. Although the Ethiopian pharmaceu-
tical market grew on average by 20% per annum from 2007 to 2011, 
it is still rather limited, estimated at around US$500 million, due 
mainly to low per capita income. Currently, there is slightly higher 
total health expenditure as a share of GDP, at 4.9% in Ethiopia, as 
compared to other countries in Africa (excluding South Africa), but 
the per capita health expenditure remains among the lowest in the 
region (Wamai, 2009). 
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 Joint ventures and strategic partnerships: fostering 
technology transfer 
 The revival of the pharmaceutical industry of Ethiopia after the boom 
and crash is largely attributed to policy reforms, investment and manu-
facturing incentive packages. One important phenomenon that stands 
out is joint ventures. Through the initiative of joint ventures, a fore-
closed factory revived, an old factory was upgraded, new factories were 
established, and enhanced technology transfer included localization of 
technical knowledge within Ethiopia. 
 One of the shortcomings of the local manufacturers is that they 
are organized at the secondary level and hence dependent on foreign 
companies for raw materials and technology sources. In order to over-
come this problem, some local manufacturers established joint ventures 
as a strategic partnership with foreign companies. These joint venture 
investors gain access to both local and regional markets, and Ethiopia’s 
cheap labour force, as well as a number of investment incentives that 
the country offers in exchange for raw materials, know-how, technology 
transfer and pre-established market networks. This kind of strategic part-
nership can be considered as a key factor for long-term success. The 
joint ventures between the Ethiopian company, Zaf Pharmaceuticals 
PLC, and two Chinese companies, China Associate (group) Co., Ltd and 
Dandong Jinwan (Group) Co., Ltd (Sino-Ethiop Associate Africa PLC), 
and between Medtech (Ethiopia) PLC and Gulf Pharmaceuticals Julphar 
of UAE (Julphar Pharmaceuticals Manufacturing Ethiopia PLC) are based 
on this principle. 
 Sino-Ethiop Associate Africa PLC, the sole empty hard gelatin capsules 
(EHGCs) manufacturer in Africa, was established at the outskirts of 
Addis Ababa in March 2001 and became operational in June 2003. 
China Associate (Group) Co., Ltd. is a 35% shareholder of Sino-Ethiop 
Associate Africa PLC. It is a diversified enterprise engaged in manufac-
turing of bulk pharmaceuticals and finished formulations and has a 
trading business. This company has more than ten years of business 
relationship with the pharmaceutical companies of some African coun-
tries, including Ethiopia. Dandong Jinwan (Group) Co., Ltd. is the other 
partner holding 35% of the shares. It is a diversified enterprise engaged 
in the production of EHGCs itself and manufacturing of equipment for 
capsules production. Zaf Pharmaceuticals PLC, engaged in importing 
of pharmaceuticals, is the Ethiopian counterpart in the joint venture, 
having 30% of the shares. 
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 The company currently has five automatic capsule production lines 
to produce EHGCs, with a total capacity of 2.4 billion EHGCs of size 0, 
size 1 and size 2 per year. The continuous batch system is applied in 
the production process; as a result, production is not interrupted except 
during regular preventive maintenance schedule and size part changes. 
Its capacity utilization is normally more than 95%, operating in three 
shifts. On average, there are more than 300 production days per year. 
The company covers 100% of the local EHGCs demand and exports to 
Sudan, Kenya, Uganda, South Africa, Ghana, Zimbabwe, Democratic 
Republic of Congo, Yemen and Saudi Arabia, among others. 
 The company has recently undergone a major expansion that trans-
formed the overall capacity of the company, doubling the annual 
output. It has also done the civil engineering required to accommodate 
three more production lines. The director of the company revealed that 
the expansion has transformed the company in terms of both quality 
and productivity, including:
 state-of-the-art manufacturing equipment which is automatic and  ●
fully synchronized; 
 Programmable Logic Controller (PLC) systems: advanced from push- ●
button to touch-screen, enabling easy process monitoring and record 
keeping; 
 heating, ventilation and air conditioning (HVAC) system: programmed  ●
based on a one-year study made on the climatic condition of the 
location in order to improve its overall efficiency; 
 water treatment system: use the double-reverse osmosis system along  ●
with electro-deionization system that reduced the use of different 
chemicals and improved the quality of the water; and 
 energy utilization: integrated a solar energy source with the existing  ●
grid supply. 
 After the expansion, the manufacturing lines were moved to the new 
plant, leaving the old facility empty. Although the company is working 
three shifts at full capacity, it is still unable to meet market demand for 
EHGCs. It is therefore planning to increase its capacity from five to eight 
lines at the new plant. Further, the company plans to convert the old 
facility into a formulation plant for contract manufacturing. The other 
plan of the company, which is also of interest to the government, is to 
look into the possibilities of developing gelatin raw materials from cattle 
bone, which is abundant in the country. 
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 Skills and technology transfer has been extensive. Over a period of ten 
years, the Chinese technical and managerial staff have been completely 
replaced by Ethiopian staff (today there is just one Chinese engineer). 
The technology has been totally transferred (by Dandong Jinwan), signi-
fying the critical role that joint ventures can play in the development of 
the pharmaceutical industry. According to the general manager of the 
company, such a smooth transfer was possible due to several comple-
mentary reasons, including the trust developed among the partners, 
the government policy to limit the number of foreign employees in a 
company, training of personnel locally and abroad, and government 
insistence that the transfer of skills and technology by partners should 
take place. 
 Julphar Pharmaceuticals Manufacturing Ethiopia PLC is another 
company established as a joint venture. Its vision is to become one of 
the leading pharmaceutical companies in Africa by the year 2020 with 
a number of product portfolios. The joint venture is formed between 
an Ethiopian company, Medtech Pharmaceuticals PLC, that holds 
45% of the shares, and a United Arab Emirates (UAE) company, Gulf 
Pharmaceuticals (Julphar), that holds 55% of the shares. The UAE partner 
is producer of various pharmaceutical products in the Middle East and in 
its other subsidiaries in Algeria. Julphar maintains a network of 11 manu-
facturing plants based in the UAE, with developments under way to open 
additional facilities in strategic countries such as Saudi Arabia, Ethiopia 
and Algeria. It supplies its generic pharmaceutical products to the global 
pharmaceuticals markets. The Ethiopian partner has been exclusively 
importing and distributing Julphar products and continued to do so for 
products being produced locally by Julphar Ethiopia as well. 4 
 This joint venture transformed a previously bankrupted manufac-
turing facility, Bethelehem Pharmaceuticals, into a viable, state-of-the-art 
facility at a cost of about US$9.17 million. Currently, it is running at full 
capacity and producing and supplying the Ethiopian market with 25 
different products (25 million bottles of syrup/suspension, 500 million 
tablets and 170 million capsules per year). In order to reach the interna-
tional market, the company has already fulfilled GMP requirements and 
is expected to be fully certified with PIC/S. 
 The company has upgraded the facility with new utilities and machin-
eries as per GMP requirements. It has put in place new HVAC system, 
state-of-the-art and fully automated reverse-osmosis water treatment 
system, and boilers for generation of pharmaceutical grade steam. 
Furthermore, to increase its product portfolio and production capacity, 
a new closed and fully automated oral liquid preparation and filling 
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line, tablet compression and blistering machines, and ointment filling 
machines have been installed and made operational. To upgrade the 
quality control system, Julphar has introduced high-performance liquid 
and gas chromatography systems and computerized stability chambers. 
To enhance the quality assurance (QA) system, the company is transfer-
ring QA documentation systems such as product dossiers, procedures 
and validation protocols from the mother company in the Gulf. 
 According to the country director of Julphar UAE, the joint venture 
has been highly encouraged by Ethiopian market access and by the 
investment policy of the government. Accordingly, Julphar has also 
earmarked an additional investment worth US$50 million to establish 
an insulin plant. To facilitate the expansion, the government of Ethiopia 
availed a plot of land for Julphar adjacent to its existing facility. This 
new investment is the first of its kind in Africa and it aims at making 
Ethiopia an insulin hub for the growing African insulin demand. 5 This 
move is heralding the beginning of advanced manufacturing of pharma-
ceuticals of biological origin in Ethiopia. 
 To achieve its vision, Julphar Ethiopia PLC is interested in launching 
new investment in additional plant to produce products like B-lactams 
and small-volume injectable products. The director reiterated the chal-
lenges the company has been facing, including lack of trained and 
skilled engineers to install and maintain pharmaceutical machineries 
and facilities and the unavailability of spare parts and consumable mate-
rials in the local market. To deal with these challenges, the company 
has assigned engineers and technicians from the mother company. This 
arrangement has helped with technology and skill transfer for Ethiopian 
engineers. To overcome the shortage of trained and skilled manpower 
in the pharmaceutical industry, the company has made arrangements 
with local universities for the provision of on-the-job training within 
its facility and abroad in its mother company. Accordingly, a team of 
selected students from different universities were fully funded by the 
company for their stay in Julphar UAE to acquire knowledge and skill 
in the pharmaceuticals manufacturing sector. 6 From the foregoing it is 
apparent that integrating health and industry polices is highly benefi-
cial for industrial development, since it can attract and make good use 
of joint ventures. 
 Socio-economic policies and the investment environment 
 The last section referred to the Ethiopian government’s incentives for 
local industry. This section explores those industrial and socio-economic 
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policies in more depth. The Ethiopian government’s industrial policies 
are developmental in nature, and pharmaceuticals are a key aspect of 
that broader approach. Consequently, the current investment climate 
of the country is considered propitious, since the country has several 
competitive advantages. Ethiopia has sizeable young and educated, 
trainable human resource and a large number of inexpensive labourers; 
rapidly developing green energy, as well as modest transportation infra-
structure and trade logistics; and duty-free, quota-free access to the US 
and EU markets under the African Growth and Opportunities Act (Assefa 
et al., 2013). 
 Both the National Health Policy (NHP) (TGE, 1993a) and the National 
Drug Policy (NDP) (TGE, 1993b) emphasize the importance of local phar-
maceutical production. The NHP states: ‘Availability of drugs, supplies 
and equipment shall be assured by encouraging national production 
capability of drugs, vaccines, supplies and equipment by giving appro-
priate incentives to firms which are engaged in manufacture, research 
and development’ (TGE, 1993a). One of the objectives of the NDP also 
specifies: ‘To develop a domestic drug manufacturing capacity and 
gradual supply to the export market’ (TGE, 1993b). Given the signifi-
cant headway Ethiopia has made in availing access to PHC for its people, 
and given the country’s ambitious local pharmaceutical manufacturing 
plans, the NDP is currently being revised to lead GTP II and GTP III. 
 The regulatory body previously known as DACA was restructured 
(with greater mandates including improved regulation, and setting 
standards in health care facilities as well manufacturing companies) and 
re-established as the Food, Medicine and Healthcare Administration 
Control Authority (FMHACA) by Proclamation, and has set standards 
for manufacturing facilities, among others (FDRE, 2009). Even though 
the primary responsibility of FMHACA is to regulate and control medi-
cines, it has been building the capacity of the local manufacturers in 
GMP in collaboration with the WHO and the United States Agency 
for International Development (USAID) programme ‘Promoting the 
Quality of Medicines’ and United States Pharmacopeial Convention 
(PQM/USP). 
 The other sectoral polices that Ethiopia has put in place that in one 
way or another have contributed to the overall socio-economic develop-
ments (including the local pharmaceutical industry) are trade policies 
(focusing on business transactions such as the pharmaceutical supply 
chain), industrial policies (focusing on fostering manufacturing and 
technology transfer) and investment and labour policies. Since the 
implementation of the 1991 Trade Policy, Ethiopia has made significant 
78 Gebre-Mariam, Tahir and Gebre-Amanuel
progress in opening up its economy and notable improvements have 
been recorded in its international trade. 
 Industry Policies 
 Ethiopia’s Industry Policy dates from August 2001 and is designed within 
the framework of a free market economy. The key principles of the 
strategy include recognition of the role the private sector as an engine 
of industrial development and facilitation by the government towards 
that end; an agricultural development-led industrialization strategy; and 
ultimately export-led industrialization. It focuses on labour-intensive 
industries and aims to coordinate foreign and domestic investment. 
 Local pharmaceutical production in developing countries has always 
been a debatable issue. On one hand, there are opinions that argue 
against local pharmaceutical production for lack of comparative advan-
tage, including absence of GMP and inadequate drug regulatory systems. 
These critics are also concerned with the immediate and long-term 
threats posed by low-quality medicines manufactured by African coun-
tries. People on the other side of the debate consider essential medicines 
as strategic commodities and seek to foster self-reliance and hence local 
production (Bate, 2008). The Ethiopian industry policy fosters the latter 
approach. 
 The investment policy within Ethiopia’s industrial policy frame-
work encourages the private sector to invest in almost all areas of 
economy. The policy does not impose local content, technology 
transfer (although encouraged) or export performance requirements 
on foreign investments. Export-oriented sectors receive long-term 
credit with low interest, export incentives, customs duty privileges 
and provision of land at competitive rents. The Development Bank 
of Ethiopia offers up to 70% of the investment capital for new invest-
ments or expansion projects in the pharmaceutical sector, with a 
7.5% interest rate and a long-term repayment horizon. Investors in 
the manufacturing sector will have customs duty privileges for capital 
goods and construction materials necessary for the investment, spare 
parts whose value is not greater than 15% of the total value of the 
capital goods and tax holiday privileges between two and seven years. 
There are no restrictions on repatriation of earnings, capital, fees or 
royalties (EIC, 2014). 
 Recognizing the role of the private sector in the economy, the govern-
ment of Ethiopia revised its investment law at least three times between 
1992 and 2012. The revisions rendered investment incentives more trans-
parent, attractive and competitive. Major positive changes regarding 
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foreign investments have also been introduced through Investment 
Proclamation No.769/2012 and Regulation No. 270/2012, which detail 
the tax incentives and duty-free privileges for investors. 
 In general, there are a number of reasons for potential investors to 
consider Ethiopia as a desirable location for pharmaceutical invest-
ment, including factors such as investor-friendly policies, conducive 
macroeconomic policies and stable foreign exchange rates, a sizeable 
local market, access to the markets of several African countries through 
COMESA, preferential trade treatment to the EU, ACP-EU, a favourable 
export market under the US Generalized System of Preference, abundant 
and inexpensive skilled and trainable workforce, strategic location with 
proximity to the lucrative markets of the Middle East, Europe and Asia 
and attractive incentive packages for investment. 
 Ethiopia is a member of the World Bank–affiliated Multilateral 
Investment Guarantee Agency, which gives foreign investors guarantees 
against non-commercial risks. Ethiopia is a signatory to several bilat-
eral and multilateral investment promotion and protection treaties. 
Ethiopia has also signed the World Bank Treaty on ‘The Convention 
on Settlement of Investment Disputes between States and Nationals of 
other States’. 
 The country’s current labour policy is based on Labour Proclamation 
No. 377/2003 which calls for workers and employers to comply with 
basic principles of rights and obligations, through co-operative efforts 
(FDRE, 2004) in conformity with international conventions and other 
legal commitments to which Ethiopia is a party. Abundance of inexpen-
sive and disciplined labour together with the introduction of the revised 
labour proclamation is believed to contribute positively towards compe-
tition in the industry and other sectors. 
 Science and technology policies 
 One of the key indicators of the socio-economic development and tech-
nological progress of a country is the contribution of the industrial 
sector to the economy. The Ethiopian government has recognized that 
science and technology are the major driving forces behind industriali-
zation. It is taking steps to foster the growth of science, technology and 
innovation (STI), including the promotion of indigenous knowledge to 
tackle the country’s needs (see also Chapter 7). 
 The Ministry of Science and Technology (MoST) recently published a 
document called the ‘Green Paper on Science, Technology and Innovation 
Policy of Ethiopia-Building Competitiveness through Innovation’ (MoST, 
2012). In this document the pharmaceutical industry has not only been 
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listed as one of the high-level technology industries but also identified 
as an area in which efforts will be geared to building domestic techno-
logical capability. According to the paper, the pharmaceutical industry 
is among the National Priority Technology Capability Programmes of 
Ethiopia. 
 The national science and technology policy of the country dates from 
1993. Although this policy served to provide general directions to guide 
scientific and technological activities, it was not followed by imple-
mentation strategies and programmes aimed at achieving the envisaged 
policy objectives. It was therefore revised in 2012. The revised policy 
directives and strategies indicate, among other things, that at least 1.5% 
of the country’s gross national product (GNP) will be allocated annu-
ally to support and sustain the different STI activities in all sectors. A 
centralized innovation fund for R&D activities will be created through 
a contribution of 1% of the annual profit of all productive and service 
sectors, and banking and financial institutions will be encouraged 
through various legal and incentive mechanisms to improve their role 
of fostering technological innovation (MoST, 2013). 
 The policy landscape of Ethiopia entered a new phase when the 
Ethiopian government launched the GTP I (2010/11–2014/15). As the 
highest national policy framework, the GTP governs Ethiopia’s devel-
opmental policies, budgets and government organizations, as well as 
actions of development partners and foreign investors. Among other 
things, the GTP is tuned to expand infrastructure significantly and 
increase the role of the manufacturing industry in employment and 
economic development. The GTP identifies the pharmaceutical industry 
as a priority sector. Moreover, government support for the priority 
sectors will focus on, among other things, expanding modern systems 
in the sector by using local and external technical support and ensuring 
foreign technical support and investment, focusing on management 
skills and transformation, technological transfer and capacity building. 
The market share of local pharmaceutical producers is targeted to reach 
50% by 2015 (MoFED, 2010). 
 For this set of objectives, regulatory support is essential. As part of 
the GTP, the FMHACA has been implementing a five-year project which 
states: ‘The main aim of the pharmaceutical industry is substituting 
essential medicines imported to the country and setting the ground 
for export of local products by building the capacity of existing phar-
maceutical and medical device manufacturers and establishing new 
ones’. Notwithstanding the responsibilities vested in the authority by 
Proclamation 661/2009 to ensure the safety, efficacy and quality of 
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products, the FMHACA together with stakeholders has been exerting 
efforts to build the technical capacity of local manufacturers. 
 The FMHACA’s ambitious project envisioned 17 local GMP-certified 
pharmaceutical manufacturers by the end of 2015; at least five phar-
maceutical manufacturers pre-qualified by WHO by 2015; seven newly 
established pharmaceutical manufacturers by the end of 2015; and two 
newly established pharmaceutical raw materials manufacturers and two 
newly established traditional medicines manufacturers (FMHCA, 2011). 
To build the capacities of the local pharmaceutical manufacturers, 
FMHACA also prepared the Medicine Manufacturing Establishment 
Directive, and it has made it mandatory for any person engaging in 
manufacturing medicines to obtain a Certificate of Competence from 
the Authority (FMHCA, 2013a). 
 FMHACA, working together with the WHO and USP/PQM and local 
manufacturers, prepared a five-year GMP Road Map (2013–18). It has 
assessed and mapped the GMP status of the local manufactures and cate-
gorized them into three GMP compliance levels (Level I with up to 50% 
GMP compliance; Level II with 60–80% GMP compliance; and, Level III 
with more than 80% GMP compliance). As per their levels, FMHCA and 
its partners are building the capacity of the local manufacturers for them 
to be GMP compliant by 2018 (FMHACA, 2013b). 
 A major scientific and technological project is the establishment of 
a Regional Bioequivalence Centre (RBEC) in Ethiopia. This presents 
yet another major opportunity for upgrading. To serve as substitutes, 
generic products should be bioequivalent or therapeutically equivalent 
to the originator/comparator products. Consequently, bioequivalence 
becomes even more crucial for generic products such as medicines 
for critical use (e.g. anti-retroviral, anti-tubercular), medicines with 
a narrow margin of safety (e.g. cardiovascular drugs), sustained or 
modified-release products and medicines with inherent solubility and 
permeability problems. 
 To obtain marketing authorization in different countries, manu-
facturers have to get their products approved and registered by the 
national drug registration authorities. Under normal circumstances, 
manufacturers are expected to present product pre-qualification for 
bioequivalence. However, local regulatory authorities could not enforce 
bioequivalence testing thus far, because the service fees charged by inter-
national contract research organizations are not affordable to the local 
manufacturers. Hence, the absence of a local bioequivalence testing 
facility in the subregion has been a big hurdle in the enforcement of the 
bioequivalence testing requirement of the generic medicines. 
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 To assist local manufacturers, the Regional Bioequivalence Centre Sh. 
Co. (RBEC) was recently established in Addis Ababa as a public-private 
partnership. GIZ provided the basic instruments and equipment for 
the bio-analytic laboratory and technical training to key staff. Addis 
Ababa University made available laboratory space and furnished offices. 
Two pharmaceutical manufacturing companies in Kenya (Universal 
Corporation Ltd and Skylight Chemicals Ltd), one local manufacturer 
in Ethiopia (Addis Pharmaceutical Factory PLC) and one generic manu-
facturer in Germany made modest financial contributions to cover the 
running costs of the Centre until it acquires the WHO prequalification 
and thereby begins to generate its own revenue. The Centre has a clinical 
partner, Armauer Hanssen Research Institute, where the clinical studies 
are being conducted. 
 Since RBEC is the first of its kind in the Sub-Saharan region (except 
for South Africa), the centre anticipates an overwhelming demand for 
BE studies. The Centre will also offer services related to assessment of 
quality of medicines. In the long run the RBEC would also play key role 
in clinical trials as well as in pharmaceutical research and development 
activities aiming at product development and drug discoveries. 
 The other important entity that has been recently (2013) established 
by Proclamation is the Food, Beverage and Pharmaceuticals Industry 
Development Institute, which has the objective of transforming the 
food, beverage and pharmaceutical industries through accelerated tech-
nological development and transfer. Currently, the Institute is preparing 
a 10-year strategic plan for the development of the pharmaceutical 
industry. 
 Conclusion: future pathways and challenges 
 Ethiopia is making substantial headway in all areas of socio-economic 
development. It is in the midst of a sustained growth surge that is 
becoming increasingly broad-based, building on major improvements 
in educational attainment, improved health outcomes and improved 
infrastructure capacity (power, transportation and telecommunica-
tions). The GTP sets ambitious targets for further improvements in these 
areas, together with significant reforms aiming to improve local manu-
facturing capacities (including pharmaceuticals) and trade logistics by 
rolling out various export-oriented economic programmes (Assefa et al., 
2013). 
 Despite all these achievements, however, there are still outstanding 
issues to be addressed, such as the low production capacity and 
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overwhelming dependence on importation of medicines; shortage of 
qualified management and technical personnel; and inadequate contin-
uing professional development for practising professionals. 
 Asked about challenges and limitations faced by the local manufac-
turers, the plant technical manager of EAP reiterated the following: 
limited working capital of the factories; conflicts of interest with the 
suppliers of raw materials in India and China (as they are also producers 
of medicines, so they charge higher prices); paying VAT that is not 
reimbursed; shortage of foreign currency and hence longer lead time in 
foreign purchase resulting in price fluctuation and ultimately purchase 
reorders; small bulk orders with no economy of scale; low manufac-
turing capacity and hence high production cost; and limited capacity 
for troubleshooting and management. 
 Finally, based upon the assessment in this chapter, we suggest the 
following ways forward. 
 Strengthen local production: Although some progress has been made 
over the past few years, the development and local production of medi-
cines is still marginal. Consequently, Ethiopia is relying heavily on 
imports for medicines and medical supplies. It is therefore crucial to 
build and strengthen national capacity to manufacture affordable, safe, 
efficacious, high-quality generic essential medicines which can signifi-
cantly contribute to the simultaneous achievement of public health and 
industrial development objectives (MoST, 2012). 
 Competitive and efficient local pharmaceutical production should be 
promoted by strengthening local producers’ capacity to meet WHO-GMP 
and WHO prequalification standards, promoting regional and interna-
tional collaborations and facilitate technology transfer; fostering pooled 
procurement of raw materials and other inputs. 
 Establish raw material manufacturing plants: The fact that most raw 
materials have to be imported has made the local pharmaceutical manu-
facturers less competitive against imported generic products from Asia. 
Therefore, looking for alternative local sources of some of the excipi-
ents and APIs is one important strategy to improve the competitiveness 
of the local manufacturers (Gebre-Mariam and Schmidt, 1996, 1998; 
Gebre-Mariam et al., 1996) (see also Chapter 7). The government should 
foster such an endeavour. 
 Build human capital: The availability of adequate, appropriately trained 
and well-motivated personnel endowed with requisite knowledge, skills 
and attitude to provide effective and efficient services is of paramount 
importance for the development of the pharmaceutical industry. Some 
manufacturers report that local personnel are not adequately trained 
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to carry out pharmaceutical production and business development. 
To rectify this, formal pharmaceutical training should be based on the 
needs of the industry. Strategies should be devised and implemented to 
update professionals who are in service. 
 Enhance research and development: R&D on raw materials (APIs and 
excipients) should be fostered and long-term strategy for their local 
production should be planned and implemented. Research on product 
development to make local products competitive should be enhanced. 
More favourable conditions should be created for the introduction 
of appropriate technology and know-how to vitalize the industry. To 
develop the raw material base for the pharmaceutical industry and to 
enhance the growth of a viable domestic pharmaceutical industry and 
manufacturing capacities, the government should extend its support to 
the private sector engaged in raw materials production. Research collab-
oration between universities, research institutes and local manufacturers 
should be promoted. 
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